|The XEDAR eda2r (Catalog #MBS221471) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s XEDAR can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB).
Western Blot: This item detects a band of approximately 33kDa in 293 cell lysates.
Western Blotting: Minimum Dilution: 0.5; Maximum Dilution: 2.0ug/ml. Researchers should empirically determine the suitability of the XEDAR eda2r for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The XEDAR eda2r product has the following accession number(s) (GI #314122209) (NCBI Accession #NP_001186616.1) (Uniprot Accession #Q9HAV5). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the RABBIT ANTI HUMAN XEDAR with the following immunoassay(s):
Testing Data #1 (Western blot analysis of whole cell lysates from HEH293 human epithelial kidney cells probed with Rabbit anti Human XEDAR (MBS221471) at 0.5(A), 1(B) and 2(C))
Testing Data #2 (Immunohistochemical staining of human skin with Rabbit anti Human XEDAR (MBS221471))
MBS221471 detects human X-linked ectodermal dysplasia receptor (XEDAR), a 33kD type III transmembrane protein of the TNFR (tumor necrosis factor receptor) superfamily. XEDAR is a homologue of the ectodermal dysplasia receptor (EDAR), and binds to an isoform of ectodysplasin termed EDA-A2. Binding of ectodysplasin to XEDAR results in the induction of apoptosis, and is thought to be involved ectodermal organ development. New evidence suggests XEDAR may also be involved in skeletal muscle development. Two predominant isoforms of XEDAR exist; XEDAR-s and XEDAR-L, produced by alternative splicing.
Perservative Stabilisers: 0.02% Sodium Azide. Immunogen: Recombinant human XEDAR.
Buffer Solution: Phosphate buffered saline
Antiserum Preparation: Antisera to XEDAR were raised by repeated immunisations of rabbits with highly purified antigen. Purified IgG prepared by affinity chromatography.
Target Species: Human. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing XEDAR are readily searchable from our website. Different antibodies against the same target such as XEDAR may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. The following patways have been known to be associated with this gene. XEDAR also interacts with the following gene(s): CASP8, CYLD, EDA, FADD, SLC24A5, SLC45A2, TP53, TRAF3, TRAF6.